Cargando…
A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours
Purpose. The prognosis for patients with Ewing's tumours who have metastases at presentation or who are refractory to standard chemotherapy regimens remains poor. There is therefore a need to evaluate the role of new agents. This report describes the initial results of a prospective phase II tr...
Autores principales: | Meyer, T., Mctiernan, A., Whelan, J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395514/ https://www.ncbi.nlm.nih.gov/pubmed/18521364 http://dx.doi.org/10.1080/1357714031000114192 |
Ejemplares similares
-
A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma
por: Mctiernan, Anne, et al.
Publicado: (2004) -
Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
por: Zekri, J M, et al.
Publicado: (2003) -
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer
por: Lordick, F, et al.
Publicado: (2003) -
Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution
por: McTiernan, Anne M., et al.
Publicado: (2006) -
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
por: Choy, Edwin, et al.
Publicado: (2014)